Skip to content

Endpoints News: CellFE raises $22M Series A to advance a new cell therapy manufacturing idea


Exclusive: The Cal­i­for­nia-based start­up CellFE has raised a $22 mil­lion Se­ries A to ad­vance a new ap­proach to mak­ing cell ther­a­pies with mi­croflu­idics.

Most cell ther­a­py de­vel­op­ers use hol­lowed-out virus­es to de­liv­er the ge­net­ic ed­its that make cell ther­a­pies ef­fec­tive. But those virus­es are ex­pen­sive and dif­fi­cult to man­u­fac­ture and al­so lim­it­ed in the size of what they can car­ry. CellFE CEO Al­la Za­ma­raye­va told End­points News that the com­pany is try­ing a dif­fer­ent ap­proach by us­ing tiny, mi­croflu­idic chips in­stead of virus­es to mod­i­fy cells…

Read the rest of the article here.

Originally published via Endpoints News.